QGel
QGel is a Swiss drug-discovery company founded in 2009 and based in Lausanne. It appears to develop hydrogel- or assay-based technology for pharmaceutical and biotech R&D customers, though no products, customers, or revenue model are disclosed and its web presence is currently inactive.
- Company typePrivate
- Founded2009
- HeadquartersLausanne, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
QGel firmographics
Firmographics- Name
- QGel
- Website
- https://qgelbio.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- QGel is a Swiss drug-discovery company founded in 2009 and based in Lausanne. It appears to develop hydrogel- or assay-based technology for pharmaceutical and biotech R&D customers, though no products, customers, or revenue model are disclosed and its web presence is currently inactive.
- Ownership category
- akta.pro rank
QGel industry classification
Industry- Product category
- Drug Discovery Tools
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where QGel is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
QGel business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
QGel product offering
Product offeringCore offering
QGel is a drug discovery company developing innovations in pharmaceutical research. The company's website (qgelbio.com) currently displays a Namecheap domain parking page, and no specific products, services, or detailed offerings are documented in the available source data.
Differentiator
Problem solved
Functional benefit
Companies that use QGel
Customer profileIdeal customer profiles1 record
QGel technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
QGel competitors and assessment
Company assessmentEmerging players
- TissUse: TissUse develops multi-organ-on-chip platforms that, like 3D matrix products, aim to replace or augment traditional in vitro models for drug screening. It is a complementary technology targeting the same pharma preclinical customers.
- InSphero: InSphero is a Swiss-based specialist in 3D microtissue and organoid technology for drug discovery and toxicity testing. It addresses overlapping customer use cases (preclinical screening) and is a credible co-development or licensing counterpart.
- Xcell Biosciences: Xcell Biosciences builds cell-culture instrumentation and consumables for physiologically relevant in vitro models, including tumor and immune-cell applications. It competes in adjacent cell-culture technology used by the same pharma discovery customers.
- Organovo: Organovo focuses on 3D bioprinted human tissues for drug discovery and disease modeling. While its delivery modality (bioprinted tissue) differs from QGel's hydrogels, both companies target pharma customers seeking more predictive in vitro assays.
Broad incumbents
- Bio-Techne: Bio-Techne (formerly R&D Systems) sells Cultrex BME and a broad portfolio of reagents and proteins used in cell culture, organoids, and drug screening. It competes directly with QGel's matrix products while also offering the broader reagent catalog that customers buy alongside.
- MilliporeSigma: MilliporeSigma (the life-science arm of Merck KGaA) sells ECM products, cell-culture reagents, and organoid workflows to pharma and academic customers. It competes with QGel across the matrix and 3D-culture workflow stack.
- Corning Life Sciences: Corning manufactures Matrigel and other extracellular-matrix products that are the default substrate for 3D cell culture and organoid work. It is the most entrenched incumbent in QGel's core addressable market and sets the competitive benchmark for synthetic-matrix substitutes.
- Thermo Fisher Scientific: Thermo Fisher distributes Geltrex and other basement-membrane-extract reagents through its life-sciences portfolio and is a one-stop supplier for pharma screening labs. Its scale and channel access make it the dominant go-to-market benchmark in the category.
Others
- Lonza: Lonza is a Swiss-headquartered CDMO and cell-therapy manufacturer with deep relationships across pharma R&D. It is comparable to QGel as a Switzerland-based life-sciences enabler and a potential partner or acquirer for cell-culture and screening technologies.
Direct peers
- STEMCELL Technologies: STEMCELL Technologies supplies defined, animal-component-free cell-culture media, matrices, and organoid kits for pharma and academic customers. Its defined-matrix product line is the closest like-for-like commercial alternative to QGel's synthetic hydrogels.
Market position
Customer concentration
QGel social profiles
Digital presenceQGel financial estimates
Financial estimateRevenue estimate
Valuation estimate
QGel leadership team
Management profileNumber of profiles
Profiles2 records
QGel funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
QGel M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about QGel
What does QGel do?
QGel is a drug discovery company developing innovations in pharmaceutical research. The company's website (qgelbio.com) currently displays a Namecheap domain parking page, and no specific products, services, or detailed offerings are documented in the available source data.
When was QGel founded?
QGel was founded in 2009. It employs 1 to 10 people.
Where is QGel based?
QGel is headquartered in Lausanne, Switzerland, in the Europe region.
Who are QGel's main competitors?
Emerging players on record are TissUse, InSphero, Xcell Biosciences and Organovo. Broad incumbents are Bio-Techne, MilliporeSigma, Corning Life Sciences and Thermo Fisher Scientific. Lonza is listed as an others. STEMCELL Technologies is listed as a direct peer.
Does QGel have an API?
No public API is recorded for QGel.
What industry is QGel in?
QGel's product category is Drug Discovery Tools. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714.